<?xml version="1.0" encoding="UTF-8"?>
<p id="par0025">Since December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused an outbreak of respiratory illness termed Coronavirus Disease 2019 (COVID-19) globally [
 <xref rid="bib0005" ref-type="bibr">1</xref>,
 <xref rid="bib0010" ref-type="bibr">2</xref>]. The disease has become a global pandemic, threatening billions of people and leading to over 730,000 death worldwide [
 <xref rid="bib0015" ref-type="bibr">3</xref>]. At the late March, the epidemic had been under control in China with the strong and sustained efforts of the whole country. Despite many previous articles report mainly concentrating on the epidemiological findings and clinical characteristics of patients with COVID-19 in Hubei province and outside of Hubei [
 <xref rid="bib0020" ref-type="bibr">[4]</xref>, 
 <xref rid="bib0025" ref-type="bibr">[5]</xref>, 
 <xref rid="bib0030" ref-type="bibr">[6]</xref>], the clinical experience in Guangzhou, a non-epidemic area but with high risk of imported cases from abroad, is still very valuable for controlling this emerging disease.
</p>
